Physician profile
Anika Cherry
NPI 1497075105
$2,978.84
in general payments reported to CMS, 2019-2025
32 companies · $342 in 2025
The $342 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $528 · 2020: $306 · 2021: $676 · 2022: $415 · 2023: $385 · 2024: $326 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,054.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,053.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $898.58 | 2019-2025 | Orilissa |
| Minerva Surgical, INC | $287.68 | 2019-2023 | |
| Pfizer INC. | $240.68 | 2019-2023 | |
| Mayne Pharma Commercial LLC | $174.80 | 2022-2025 | |
| Exeltis, USA INC. | $168.21 | 2019-2024 | Slynd |
| Hologic Sales and Service, LLC | $152.26 | 2020-2024 | Myosure Tissue Removal Device, Coolseal Generator, Novasure |
| Evofem Biosciences, INC. | $127.79 | 2021-2024 | Phexxi |
| Sumitomo Pharma America, INC. | $109.91 | 2023-2025 | Myfembree, Gemtesa |
| Biogen, INC. | $107.83 | 2025 | Zurzuvae |
| Intuitive Surgical, INC. | $85.88 | 2022 | |
| Myovant Sciences INC. | $78.92 | 2021-2022 | |
| Organon LLC | $52.09 | 2025 | Nexplanon, Jada System |
| Amag Pharmaceuticals, INC. | $48.40 | 2019-2020 | |
| Exact Sciences Corporation | $43.63 | 2023-2024 | Cologuard Collection Kit |
| Lupin INC. | $36.08 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $31.59 | 2023 | Exparel |
| Avion Pharmaceuticals | $31.37 | 2022-2023 | Balcoltra |
| Shield Therapeutics INC | $31.01 | 2024 | |
| Viiv Healthcare Company | $29.38 | 2025 | Apretude |
| Therapeuticsmd, INC. | $28.81 | 2019-2020 | |
| Daiichi Sankyo INC. | $25.58 | 2025 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $22.25 | 2025 | |
| Sanofi Pasteur INC. | $22.02 | 2025 | |
| Roche Diagnostics Corporation | $21.72 | 2019 | |
| Gilead Sciences, INC. | $18.52 | 2025 | |
| Coopersurgical, INC. | $17.06 | 2020 | |
| Currax Pharmaceuticals LLC | $16.05 | 2022 | |
| Meditrina | $15.81 | 2024 | |
| Heron Therapeutics, INC. | $15.64 | 2023 | Zynrelef |
| Conmed Corporation | $13.75 | 2022 | |
| Mylan Pharmaceuticals INC. | $12.84 | 2020 | |
| Duchesnay USA Incorporated | $12.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anika Cherry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.